FDA "Drug Watch": Companies Will Have No Input On Content Prior To Posting
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors will be notified before products are listed on FDA's drug safety website but will not be given an opportunity to comment on the information ahead of time, Office of New Drugs Director Jenkins says. FDA will be "cautious" regarding the extrapolation of individual product data across a class.